Table 3 ∣.
Ongoing clinical trials in HFpEF
| Status | Study Title | Interventions | Conditions |
|---|---|---|---|
| Pharmaceutical | |||
| Active | DETERMINE-preserved | Dapagliflozin | HFpEF |
| Active | Developing Oral LT3 Therapy for Heart Failure - HFpEF | liothyronine | Low Triiodothyronine Syndrome |
| Active | (KNO3CK OUT HFPEF) | Drug: Potassium Nitrate (KNO3), Drug: Potassium Chloride (KCl) | HFpEF |
| Active | (EMPEROR-Preserved) | Empagliflozin | HFpEF |
| Active | Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction | Sodium Nitrite | HFpEF and secondary PH |
| Active | Metformin for Pulmonary Hypertension HFpEF | Metformin | HFpEF with Secondary PH |
| Active | AZD9977 and Spironolactone on Serum Potassium | AZD9977: Spironolactone | HFpEF |
| Active | Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients | Levosimendan 2.5 mg/ml Injectable Solution | HFpEF with PH |
| Active | The Efficacy and Safety of Pirfenidone in HF and Preserved Left Ventricular Ejection Fraction | Pirfenidone | HFpEF |
| Recruiting | Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan. | Drug: LCZ696 | HFpEF |
| Recruiting | Effect AZD4831 in Japanese and Chinese Healthy Volunteers | Drug: AZD4831 | HFpEF |
| Recruiting | Transthyretin Cardiac Amyloidosis in HFpEF | Drug: 99mTc-PYP | HFpEF |
| Recruiting | Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction | Drug: Entresto™ 49Mg-51 mg tablet | HFpEF |
| Recruiting | Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction | Drug: Ferric Carboxymaltose 50Mg/Ml Inj 15Ml | Iron-deficiency, HFpEF |
| Recruiting | Dapagliflozin Evaluation to Improve the LIVEs of Patients with Preserved Ejection Fraction Heart Failure. | Dapagliflozin | HFpEF |
| Recruiting | MPO Inhibitor A_Zeneca for HFpEF | Oral Myeloperoxidase Inhibitor | HFpEF |
| Recruiting | Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | Spironolactone | HFpEF |
| Recruiting | LCZ696 in Advanced LV Hypertrophy and HFpEF | Drug: LCZ 696 Drug: Valsartan |
HFpEF with Essential Hypertension |
| Recruiting | A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction | Drug: 15N Nitrate Drug: 14N Nitrate |
HFpEF, PH |
| Recruiting | A Trial to Study BAY1753011 in Patients With Congestive Heart Failure | Drug: BAY 1753011 Other: Placebo BAY 1753011 Drug: Furosemide Other: Placebo Furosemide |
HFrEF and HFpEF |
| Recruiting | Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs | Biological: Allogeneic Derived Cells Biological: Placebo/Control Arm |
HFpEF with Diastolic Dysfunction |
| Recruiting | Dapagliflozin in PRESERVED Ejection Fraction Heart Failure | Drug: Dapagliflozin 10Mg Oral Tablet Drug: Dapagliflozin matching placebo |
HFpEF |
| Recruiting | β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR) | Drug: Controlled withdrawal of beta-blockers | HFpEF, Chronotropic Incompetence |
| Recruiting | Cell Therapy in HFpEF | Cell Therapy | HFpEF |
| Recruiting | INABLE-Training | Drug: Oral Sodium Nitrite Device: Accelerometer Other: Cardiac Exercise Training |
HFpEF |
| Recruiting | Changes in NT-proBNP and Outcomes, Safety, and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF) Link |
Drug: sacubitril/valsartan Drug: valsartan |
HFpEF |
| Not yet recruiting | Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF | Pioglitazone Plus dapaglifliozin | HFpEF and HFrEF |
| Enrolling by invitation | A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE OL) | Drug: macitentan 10 mg | HFpEF with Pulmonary Vascular Disease |
| Completed | A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients | Drug: sacubitril/valsartan Drug: Enalapril Drug: Valsartan |
HFpEF |
| Completed | The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction | Drug: Pirfenidone Drug: Placebo |
HFpEF |
| Terminated | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction | Drug: Oral treprostinil Drug: Placebo |
HFpEF with PH |
| Not yet recruiting | Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction | HFpEF | Carvedilol SR |
| Not yet recruiting | Study of Verinurad in Heart Failure With Preserved Ejection Fraction | HFpEF | Drug: Verinurad Drug: Allopurinol Drug: Placebo for verinurad Drug: Placebo for allopurinol |
| Devices | |||
| Recruiting | CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) | Diastolic Heart Failure, Diastolic Dysfunction | Device: CORolla™ TAA device |
| Recruiting | Endovascular GSN Ablation in Subjects With HFpEF | HFpEF | Device: Ablation |
| Recruiting | CCM in Heart Failure with Preserved Ejection Fraction | Heart Failure, Diastolic | Device: Optimizer SMART |
| Recruiting | Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure | Heart Failure, Diastolic, Chronotropic Incompetence | Device: Rate adaptive atrial pacing using a dual-chamber pacemaker Device: Pacemaker system will be implanted but set to Pacing Off. |
| Active Not Recruiting | REDUCE LAP-HF RANDOMIZED TRIAL I | Device: Inter-Atrial Shunt Device Other: Intracardiac Echo |
Heart Failure |
| Not yet recruiting | 3-Month Home-based Training With Whole Body Vibration (WBV) Device in Patients With Heart Failure and Preserved Ejection Fraction (GALILEO-HFpEF-HOME) (GALILEOHOME) | HFpEF | Device: Group 1 GALILEO WBV Other: Group 2 Control |
| Recruiting | REDUCE LAP-HF TRIAL II | Device: VitalPatch Biosensor Device: DynaPort Move Monitor |
Heart Failure |
| Recruiting | Reducing Lung CongestIon Symptoms in Advanced Heart Failure | Device: V-Wave Interatrial Shunt Other: Control |
Heart Failure |
| Recruiting | Hemodynamic-GUIDEd Management of Heart Failure | Device: CardioMEMS™ HF System | Heart Failure Heart Failure, Systolic Heart Failure, Diastolic |